Aztiq and Innobic Consortium Acquires Alvogen Emerging Markets Holdings for $500M

Aztiq Pharma Partners Invests $100M to Buy 17% Stake in Alvogen US

June 30, 2021

Pharmaceuticals

Aztiq Pharma Partners completed a $100 million financing to acquire a newly issued 17% equity stake in Alvogen US at a pre-money valuation of $350 million, with Morgan Stanley leading the financing. The funding will support increased R&D investment and expansion of branded sales channels in the U.S., and following the transaction Aztiq holds a combined direct and indirect stake of approximately 40% in Alvogen US.

AstraZeneca (Alexion) to Acquire Amolyt Pharma for up to $1.05B

March 14, 2024

Biotechnology

AstraZeneca, via its Alexion Rare Disease business, has agreed to acquire clinical-stage biotechnology company Amolyt Pharma for $800 million upfront plus up to $250 million in milestone payments (total consideration up to $1.05 billion). Amolyt, based in Lyon, France (with a presence in Boston, US), is developing peptide therapeutics for rare endocrine diseases including lead asset eneboparatide (AZP-3601), currently in Phase 3; the deal is expected to close in 3Q 2024 subject to customary conditions.

Aditxt Inc. Signs Share Exchange Agreement to Acquire AiPharma Global Holdings LLC

December 28, 2021

Biotechnology

Aditxt Inc. (Nasdaq: ADTX) signed a share exchange agreement to acquire AiPharma Global Holdings LLC, a wholly owned subsidiary of AiPharma Group Ltd., in a two-step transaction that initially transfers a 9.5% interest followed by the remaining 90.5% subject to closing conditions and shareholder/Nasdaq approvals. The deal would give Aditxt commercial presence in infectious disease therapeutics and access to AiPharma's rights to Avigan (favipiravir) and related antiviral assets and distribution networks.

Alkermes plc Acquires Avadel Pharmaceuticals plc

February 12, 2026

Pharmaceuticals

Alkermes plc completed its all-cash acquisition of Avadel Pharmaceuticals plc under an Irish High Court‑sanctioned scheme of arrangement, adding Avadel's FDA‑approved product LUMRYZ to Alkermes' commercial portfolio. The deal accelerates Alkermes' entry into the sleep medicine market, is expected to be accretive in 2026, and includes Avadel's clinical candidate valiloxybate.

Amgen Completes Acquisition of Horizon Therapeutics plc

October 6, 2023

Biotechnology

Amgen completed the acquisition of Horizon Therapeutics plc for $116.50 per share in cash, valuing the transaction at approximately $27.8 billion. The deal expands Amgen's inflammation and rare-disease portfolio by adding Horizon's medicines (including TEPEZZA, KRYSTEXXA and UPLIZNA) and strengthens Amgen's biologics R&D, manufacturing and global commercial capabilities.

Fulgent Genetics Acquires Fulgent Pharma

November 7, 2022

Biotechnology

Fulgent Genetics completed the acquisition of Fulgent Pharma Holdings for approximately $100 million in a combination of cash and Fulgent common stock. The deal integrates Fulgent Pharma’s nanoencapsulation drug-delivery platform and clinical-stage oncology pipeline with Fulgent Genetics’ diagnostics capabilities to create a vertically integrated precision-medicine offering focused on cancer.